by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug… Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants...
by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials
Researchers from Liverpool School of Tropical Medicine (LSTM) have completed a Phase I clinical trial for a new oral treatment for snakebite. Researchers from Liverpool School of Tropical Medicine (LSTM) have completed a Phase I clinical trial for a new oral...
by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials
Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two immunotherapies … Researchers conducting a clinical trial of...
by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials
There are also 60 sites in the process of launching the EAP. There are also 60 sites in the process of launching the EAP.
by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials
20/20 Onsite is proud to announce its recognition with the Safety Excellence Award by Whip Around. 20/20 Onsite is proud to announce its recognition with the Safety Excellence Award by Whip Around.
by palligoelme@gmail.com | Mar 13, 2025 | Clinical Trials
Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals with AML and MDS. Cantargia has enrolled the first patient in the Phase Ib/IIa trial of nadunolimab for treating individuals with AML and...
